HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

ClinicalTrials.gov Identifier: NCT03940352

Novartis Reference Number: CHDM201H12101C

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

This is a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 or venetoclax in subjects with AML or high-risk MDS.

For all subjects, TP53wt status must be characterized by, at a minimum, no mutations noted in exons 5, 6, 7 and 8.

Two treatment arms will enroll subjects in parallel to characterize the safety, tolerability, PK, PD and preliminary antitumor activity of HDM201+MBG453 (treatment arm 1) and HDM201+venetoclax (treatment arm 2).

In the treatment arm 1, subjects will receive HDM201 in combination with MBG453.
In the treatment arm 2, subjects will receive HDM201 in combination with venetoclax. Venetoclax dose will be gradually increased (ramp-up) over a period of 4 to 5 days to achieve the daily target dose tested that will be subsequently continued.

Upon the completion of the escalation part, MTD(s) and/or RD(s) of HDM201 in combination with MBG453 or venetoclax in AML and high-risk MDS subjects will be determined for each treatment arm.

Condition 
Acute Myeloid Leukemia (AML)
High-risk Myelodysplastic Syndrome (MDS)
Phase 
Phase 1
Overall status 
Recruiting
Enrollment count 
80 participants
Start date 
Jun 24, 2019
Completion date 
Apr 22, 2021
Gender 
All
Age(s)
18 Years and older (Adult, Older Adult)

Interventions

Drug
HDM201
Capsule
Biological
MBG453
LIVI (Liquid in vial) Concentrate for Solution for infusion
Drug
Venetoclax
Tablet

Eligibility Criteria

Main Inclusion Criteria:

Male or female patients ≥ 18 years of age at the date of ICF signature who present with one of the following:

Relapsed/refractory AML following ≥1 prior therapies (but ≤3 prior therapies) who have relapsed or exhibited refractory disease (primary failure) and are deemed by the Investigator not to be candidates for standard therapy, including re-induction with cytarabine or other established chemotherapy regimens for patients with AML (patients who are suitable for standard re-induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded)
First line AML patient unfit for standard induction chemotherapy (includes both de novo and secondary AML), except in countries where approved therapies are available. Patients who are suitable for hematopoietic stem cell transplantation and willing to receive it are excluded.
High-risk MDS patient (high and very high-risk groups according to rIPSS) who have failed hypomethylating agent therapy.
ECOG performance status ≤ 1
TP53wt tumor. At minimum exons 5, 6, 7 and 8 in the TP53 gene must be sequenced and determined to contain no mutations. The TP53 status must be obtained from a bone-marrow sample, collected no longer than 3 months before signing the main ICF.
Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to the institutional guidelines and be willing to undergo a bone marrow aspirate and/or biopsy at screening, during and at the end of therapy on this study. Exceptions may be considered after documented discussion with Novartis.

Main Exclusion Criteria:

Patients eligible for this study must not meet any of the following criteria:

Prior combination treatment with compounds having the same mode of action:

mdm2 or mdm4 inhibitors combined with TIM-3 inhibitors (for patients enrolled in treatment arm1)
mdm2 or mdm4 inhibitors combined with Bcl-2 inhibitor (for patients enrolled in treatment arm2)
History of severe hypersensitivity reactions to any ingredient of study drug(s) and other monoclonal antibodies (mAbs) and/or their excipients.
Patients with acute promyelocytic leukemia with PML-RARA.
Allogeneic stem cell transplant (HSCT) within last 6 months and/or active GvHD requiring systemic immunosuppressive therapy.
GI disorders impacting absorption of oral HDM201 or venetoclax.
Evidence of active bleeding or bleeding diathesis or major coagulopathy (including familial).
Patients with active, known or suspected autoimmune disease (treatment arm 1 only).

Other eligibility criteria apply.

Study Locations

United States
Novartis Investigative Site
Recruiting
Durham, 27710
North Carolina
United States
Australia
Novartis Investigative Site
Recruiting
Melbourne, 3004
Victoria
Australia
Finland
Novartis Investigative Site
Recruiting
Helsinki, FIN 00290
-
Finland
Italy
Novartis Investigative Site
Recruiting
Milano, 20132
MI
Italy
Novartis Investigative Site
Recruiting
Roma, 00161
RM
Italy
Singapore
Novartis Investigative Site
Recruiting
Singapore, 119228
-
Singapore
Spain
Novartis Investigative Site
Recruiting
Madrid, 28041
-
Spain
Switzerland
Novartis Investigative Site
Recruiting
Basel, 4031
-
Switzerland

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 
1-888-669-6682
Name: 
Novartis Pharmaceuticals
Phone: 
+41613241111
Email: 

Have a question?

Call 1-999-669-6682 or email [email protected]